These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 22659593)

  • 21. Contrast-enhanced US quantitatively detects changes of tumor perfusion in a murine breast cancer model during adriamycin chemotherapy.
    Wang JW; Cao LH; Han F; Zheng W; Chen Y; Li AH; Zhou JH
    Acta Radiol; 2013 Oct; 54(8):882-8. PubMed ID: 23761553
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Early antiangiogenic activity of SU11248 evaluated in vivo by dynamic contrast-enhanced magnetic resonance imaging in an experimental model of colon carcinoma.
    Marzola P; Degrassi A; Calderan L; Farace P; Nicolato E; Crescimanno C; Sandri M; Giusti A; Pesenti E; Terron A; Sbarbati A; Osculati F
    Clin Cancer Res; 2005 Aug; 11(16):5827-32. PubMed ID: 16115922
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intra-Animal Comparison between Three-dimensional Molecularly Targeted US and Three-dimensional Dynamic Contrast-enhanced US for Early Antiangiogenic Treatment Assessment in Colon Cancer.
    Wang H; Lutz AM; Hristov D; Tian L; Willmann JK
    Radiology; 2017 Feb; 282(2):443-452. PubMed ID: 27490690
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cluster analysis of quantitative parametric maps from DCE-MRI: application in evaluating heterogeneity of tumor response to antiangiogenic treatment.
    Longo DL; Dastrù W; Consolino L; Espak M; Arigoni M; Cavallo F; Aime S
    Magn Reson Imaging; 2015 Jul; 33(6):725-36. PubMed ID: 25839393
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice.
    Sasaki A; Boyce BF; Story B; Wright KR; Chapman M; Boyce R; Mundy GR; Yoneda T
    Cancer Res; 1995 Aug; 55(16):3551-7. PubMed ID: 7627963
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Contrast-Enhanced Ultrasound with VEGFR2-Targeted Microbubbles for Monitoring Regorafenib Therapy Effects in Experimental Colorectal Adenocarcinomas in Rats with DCE-MRI and Immunohistochemical Validation.
    Eschbach RS; Clevert DA; Hirner-Eppeneder H; Ingrisch M; Moser M; Schuster J; Tadros D; Schneider M; Kazmierczak PM; Reiser M; Cyran CC
    PLoS One; 2017; 12(1):e0169323. PubMed ID: 28060884
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tumor microvascular changes in antiangiogenic treatment: assessment by magnetic resonance contrast media of different molecular weights.
    Turetschek K; Preda A; Novikov V; Brasch RC; Weinmann HJ; Wunderbaldinger P; Roberts TP
    J Magn Reson Imaging; 2004 Jul; 20(1):138-44. PubMed ID: 15221819
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Baseline and contrast-enhanced ultrasound of the liver in tumor patients].
    Oldenburg A; Albrecht T
    Ultraschall Med; 2008 Oct; 29(5):488-98. PubMed ID: 19241505
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ultrasound Molecular Imaging With BR55, a Predictive Tool of Antiangiogenic Treatment Efficacy in a Chemo-Induced Mammary Tumor Model.
    Helbert A; Von Wronski M; Colevret D; Botteron C; Padilla F; Bettinger T; Tardy I; Hyvelin JM
    Invest Radiol; 2020 Oct; 55(10):657-665. PubMed ID: 32229739
    [TBL] [Abstract][Full Text] [Related]  

  • 30. VEGFR2-Targeted Contrast-Enhanced Ultrasound to Distinguish between Two Anti-Angiogenic Treatments.
    Payen T; Dizeux A; Baldini C; Le Guillou-Buffello D; Lamuraglia M; Comperat E; Lucidarme O; Bridal SL
    Ultrasound Med Biol; 2015 Aug; 41(8):2202-11. PubMed ID: 25980323
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Quantitative assessment of tumor blood flow in mice after treatment with different doses of an antiangiogenic agent with contrast-enhanced destruction-replenishment US.
    Zhou JH; Cao LH; Liu JB; Zheng W; Liu M; Luo RZ; Han F; Li AH
    Radiology; 2011 May; 259(2):406-13. PubMed ID: 21292869
    [TBL] [Abstract][Full Text] [Related]  

  • 32. αvß3-Integrin-Targeted Magnetic Resonance Imaging for the Assessment of Early Antiangiogenic Therapy Effects in Orthotopic Breast Cancer Xenografts.
    Kazmierczak PM; Schneider M; Habereder T; Hirner-Eppeneder H; Eschbach RS; Moser M; Reiser MF; Lauber K; Nikolaou K; Cyran CC
    Invest Radiol; 2016 Nov; 51(11):746-755. PubMed ID: 27082316
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Advanced hepatocellular carcinoma: early evaluation of response to bevacizumab therapy at dynamic contrast-enhanced US with quantification--preliminary results.
    Lassau N; Koscielny S; Chami L; Chebil M; Benatsou B; Roche A; Ducreux M; Malka D; Boige V
    Radiology; 2011 Jan; 258(1):291-300. PubMed ID: 20980447
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of treatment response of cilengitide in an experimental model of breast cancer bone metastasis using dynamic PET with 18F-FDG.
    Cheng C; Komljenovic D; Pan L; Dimitrakopoulou-Strauss A; Strauss L; Bäuerle T
    Hell J Nucl Med; 2011; 14(1):15-20. PubMed ID: 21512659
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inflammatory breast cancer: dynamic contrast-enhanced MR in patients receiving bevacizumab--initial experience.
    Thukral A; Thomasson DM; Chow CK; Eulate R; Wedam SB; Gupta SN; Wise BJ; Steinberg SM; Liewehr DJ; Choyke PL; Swain SM
    Radiology; 2007 Sep; 244(3):727-35. PubMed ID: 17709827
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A rapid histological score for the semiquantitative assessment of bone metastases in experimental models of breast cancer.
    Neudert M; Fischer C; Krempien B; Seibel MJ; Bauss F
    Onkologie; 2008 Oct; 31(10):521-7. PubMed ID: 18854651
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Use of Quantitative Dynamic Contrast-Enhanced Ultrasound to Assess Response to Antiangiogenic Therapy in Children and Adolescents With Solid Malignancies: A Pilot Study.
    McCarville MB; Coleman JL; Guo J; Li Y; Li X; Honnoll PJ; Davidoff AM; Navid F
    AJR Am J Roentgenol; 2016 May; 206(5):933-9. PubMed ID: 26999488
    [TBL] [Abstract][Full Text] [Related]  

  • 38. E-cadherin expression in human breast cancer cells suppresses the development of osteolytic bone metastases in an experimental metastasis model.
    Mbalaviele G; Dunstan CR; Sasaki A; Williams PJ; Mundy GR; Yoneda T
    Cancer Res; 1996 Sep; 56(17):4063-70. PubMed ID: 8752180
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dynamic gadobutrol-enhanced MRI predicts early response to antivascular but not to antiproliferation therapy in a mouse xenograft model.
    Dassler K; Scholle FD; Schütz G
    Magn Reson Med; 2014 May; 71(5):1826-33. PubMed ID: 23754607
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dose-response relationship in cisplatin-treated breast cancer xenografts monitored with dynamic contrast-enhanced ultrasound.
    Chen Y; Han F; Cao LH; Li C; Wang JW; Li Q; Zheng W; Guo ZX; Li AH; Zhou JH
    BMC Cancer; 2015 Mar; 15():136. PubMed ID: 25884471
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.